|View printer-friendly version|
|Xtant Medical Announces First Quarter 2018 Financial Results|
BELGRADE, MT / ACCESSWIRE / May 8, 2018 / Xtant Medical Holdings, Inc. (NYSE American: XTNT), a leader in the development of regenerative medicine products and medical devices, today reported financial and operating results for the first quarter of 2018.
First Quarter 2018 Financial Highlights and Recent Accomplishments:
"This quarter's results reflect Xtant's continued commitment to transforming the Company for operational excellence," said Carl O'Connell, Xtant Medical's chief executive officer. "We have reduced costs in numerous areas as part of our continued focus to improve net income and adjusted EBITDA performance, and are very pleased with the corporate restructuring transactions announced during first quarter 2018."
First Quarter 2018 Financial Results
Revenue for the first quarter of 2018 was $17.9 million, down from $22.1 million compared to the same period of the prior year. The year over year decline was due to a shift in our sales channels, our efforts to move away from some reseller and higher-than-acceptable commission rate distributor relationships, and competitive factors affecting the sell through of our fixation products.
Gross margin for the first quarter of 2018 was 68.2%, up from 67.5% for the same period in 2017. This improvement was due to cost containment initiatives and improvements in end user pricing by modifying and exiting certain reseller relationships.
Operating expenses for the first quarter were 77.4% of net revenue, down $3.6 million compared to the quarter ended March 31, 2017 which was 79.1% of net revenue. The improvement was mostly attributable to execution of our channel strategy enhancement initiative as we move away from higher-commission relationships and unprofitable revenue. In addition, the Company successfully continued the successful execution of its cost saving program throughout the quarter.
General and administrative expenses decreased 26.7% to $3.0 million for the first quarter of 2018, compared to the same period of 2017. The improvement is primarily due to a reduction in payroll expense from consolidating manufacturing and distribution to a single location, and from efficiencies realized by streamlining administrative functions within the business.
Net loss for the quarter was $5.3 million compared to a loss of $5.8 million for the same period in the prior year. Non-GAAP Adjusted EBITDA for the first quarter of 2018 was approximately $1.1 million compared to a loss of $0.1 million for the same period during 2017. The Company defines Adjusted EBITDA as net income/loss from operations before depreciation, amortization, non-recurring expenses and non-cash stock-based compensation. A calculation and reconciliation of net loss to non-GAAP Adjusted EBITDA can be found in the attached financial tables.
Cash and cash equivalents at the end of the first quarter of 2018 totaled $6.2 million, compared to $2.9 million as of December 31, 2017. The Company also had $2.2 million in availability under its credit facility as of March 31, 2018.
In the first quarter of 2018, Xtant entered into a restructuring and exchange agreement with holders of Xtant's outstanding 6% convertible senior unsecured notes due 2021. Pursuant to that agreement, all outstanding convertible notes, constituting $71.9 million in outstanding principal amount, plus accrued and unpaid interest, were converted into 10.6 million shares of Xtant common stock during the first quarter of 2018. Most of the conversions occurred on February 14, 2018, after the receipt of stockholder approval of aspects of the restructuring transaction and the effectiveness of a 1-for-12 reverse stock split, which occurred at the close of business on February 13, 2018. On February 14, 2018, the Company issued 945,819 shares of common stock in a private placement at a price per share of $7.20 for cash proceeds of $6.8 million.
The Company also announced the resignation of its then current board of directors and election of six new directors to serve on Xtant's board of directors.
As the final step of the restructuring, the Company recently announced April 27, 2018 as the record date for a proposed rights offering of its shares of common stock. At the commencement of the rights offering, each holder of common stock will receive 0.0869816 non-transferable subscription rights for each share of common stock held on the record date. Each whole subscription right will entitle the holder to purchase one share of the Company's common stock for $7.20 in cash. In addition, holders as of the record date will have over-subscription rights, pursuant to which they may be able to purchase additional shares at the subscription price, to the extent that not all subscription rights are exercised, subject to certain limitations. The Company expects that subscription materials will be mailed on or about May 18, 2018 to holders of the Company's common stock as of the record date, and that the rights offering will close on or about June 18, 2018. The Company may extend the rights offering for additional periods of time in its sole discretion.
The Company will host a conference call to discuss the first quarter 2018 financial results and business developments on Wednesday, May 9, 2018 at 9:00 AM EDT. Please refer to the information below for conference call dial-in information and webcast registration:
Conference date: May 9, 2018, 9:00 AM ET
Following the live call, a replay will be available on the Company's website, www.xtantmedical.com, under "Investor Info."
About Xtant Medical
Xtant Medical develops, manufactures and markets regenerative medicine products and medical devices for domestic and international markets. Xtant Medical products serve the specialized needs of orthopedic and neurological surgeons, including orthobiologics for the promotion of bone healing, implants and instrumentation for the treatment of spinal disease, tissue grafts for the treatment of orthopedic disorders, and biologics to promote healing following cranial, and foot and ankle surgeries. With core competencies in both biologic and non-biologic surgical technologies, Xtant Medical can leverage its resources to successfully compete in global neurological and orthopedic surgery markets. For further information, please visit www.xtantmedical.com.
Non-GAAP Financial Measures
To supplement the Company's consolidated financial statements prepared in accordance with U.S. generally accepted accounting principles (GAAP), the Company uses certain non-GAAP financial measures in this release, including Adjusted EBITDA. Reconciliations of the non-GAAP financial measures used in this release to the most comparable GAAP measures for the respective periods can be found in tables later in this release. The Company's management believes that the presentation of these measures provides useful information to investors. These measures may assist investors in evaluating the company's operations, period over period. Management uses the non-GAAP measures in this release internally for evaluation of the performance of the business, including the allocation of resources. Investors should consider non-GAAP financial measures only as a supplement to, not as a substitute for or as superior to, measures of financial performance prepared in accordance with GAAP.
Important Cautions Regarding Forward-looking Statements
This press release contains certain disclosures that may be deemed forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to significant risks and uncertainties. Forward-looking statements include statements that are predictive in nature, that depend upon or refer to future events or conditions, or that include words such as ''continue,'' ''efforts,'' ''expects,'' ''anticipates,'' ''intends,'' ''plans,'' ''believes,'' ''estimates,'' ''projects,'' ''forecasts,'' ''strategy,'' ''will,'' ''goal,'' ''target,'' ''prospects,'' ''potential,'' ''optimistic,'' ''confident,'' ''likely,'' ''probable'' or similar expressions or the negative thereof. Statements of historical fact also may be deemed to be forward-looking statements. We caution that these statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors, including, among others: the ability to increase revenue; the ability to achieve expected results; the ability to remain competitive; the ability to innovate and develop new products; the ability to engage and retain qualified technical personnel and members of the Company's management team; influence by Company management; the security of our technology systems; government and third-party coverage and reimbursement for Company products; the ability to obtain donors to support the biologic portfolio; the availability of Company facilities; the ability to remain accredited with the American Association of Tissue Banks; the ability to obtain regulatory approvals; government regulations; product liability claims and other litigation to which we may be subjected; product recalls and defects; timing and results of clinical studies; the ability to obtain and protect Company intellectual property and proprietary rights; infringement and ownership of intellectual property; the ability to use net operating loss carry-forwards to offset future taxable income; the ability to service Company debt; the ability to comply with covenants in the Company's senior credit facility; the ability to raise additional financing and other factors. Additional risk factors are listed in the Company's Annual Report on Form 10-K for the year ended December 31, 2017 filed with the Securities and Exchange Commission (SEC) on April 2, 2018 and subsequent SEC filings by the Company, including without limitation its Quarterly Report on Form 10-Q for the quarter ended March 31, 2018. Investors are encouraged to read the Company's filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. Investors should not place considerable reliance on the forward-looking statements contained in this release. The Company undertakes no obligation to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. The Company's business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties. All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by this cautionary statement.
XTANT MEDICAL HOLDINGS, INC.
XTANT MEDICAL HOLDINGS, INC.
XTANT MEDICAL HOLDINGS, INC.
XTANT MEDICAL HOLDINGS, INC.
SOURCE: Xtant Medical Holdings, Inc.